Global Hodgkins Lymphoma Therapeutics Market 2014-2018

世界のホジキンリンパ腫治療/医薬品市場(2014-2018)

◆タイトル:Global Hodgkins Lymphoma Therapeutics Market 2014-2018
◆商品コード:IRTNTR3907
◆調査・発行会社:Technavio (Infiniti Research Ltd.)
◆発行日:2014年8月6日
◆ページ数:79
◆資料形式:pdf / 英語
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬、医療
◆販売価格オプション(消費税別)
Single UserUSD2,500 ⇒換算¥275,000見積依頼/購入/質問フォーム
Five UserUSD2,800 ⇒換算¥308,000見積依頼/購入/質問フォーム
Enterprise License(社内共有可)USD3,500 ⇒換算¥385,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、資料に記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はTechnavio (Infiniti Research Ltd.)の日本における正規販売代理店です。

【資料の概要】

本調査レポートでは、"世界のホジキンリンパ腫治療/医薬品市場(2014-2018)"について調査・分析し、エグゼクティブサマリー、市場概観、市場規模及び予測、主要地域別分析、市場シェア、購買基準、市場成長要因、市場の課題、市場動向、競争状況、主要企業(ベンダー)分析等の情報をお届けいたします。

About Hodgkin’s Lymphoma
Hodgkin’s Lymphoma (HL) is defined as the cancer of the lymph tissue, which is part of our immune system. The exact etiology of HL is unknown. However, the risk of developing the condition is increased if a person suffers from a medical condition that weakens the immune system. In HL, cells in the lymphatic system grow unusually and may spread beyond the lymphatic system. The infection-fighting properties of the lymphocytes are lost, making the person more susceptible to infection. The main treatments used are chemotherapy, followed by radiotherapy or chemotherapy alone. Generally surgery is not used as a treatment for the condition.

TechNavio’s analysts forecast the Global Hodgkin’s Lymphoma Therapeutics market will grow at a CAGR of 6.84 percent over the period 2013-2018.

Covered in this Report
The Global Hodgkin’s Lymphoma Therapeutics market can be divided into eight segments: Alkylating Antineoplastic Agents, Antibiotic Antineoplastic Agents, Antineoplastics Vinca Alkaloid Agents, Podophyllotoxin Derivative Antineoplastic Agents, Antimetabolite Antineoplastic Agents, Anthracycline Antineoplastic Agents, Antimicrotubular Antineoplastics, and Corticosteroids. To calculate the market size, the report considers the revenue generated from the sales of various drugs used in the treatment of HL that are available in the market.
TechNavio’s report, the Global Hodgkin’s Lymphoma Therapeutics Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Hodgkin’s Lymphoma Therapeutics market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
Key Regions
• Americas
• APAC
• EMEA
Key Vendors
• Bristol Myers Squibb Co.
• F. Hoffmann-La Roche Ltd.
• Merck & Co. Inc.
• Pfizer Inc.
Other Prominent Vendors

• 4SC AG
• Actinium Pharmaceuticals Inc.
• Aeterna Zentaris Inc.
• Affimed Therapeutics AG
• Hospira Inc.
• Incyte Corp.
• Novartis AG
• Philogen S.p.A.
• Seattle Genetics Inc.
• Sigma-Tau Pharmaceuticals Inc.
• Stemline Therapeutics Inc.
• Teva Pharmaceutical Industries Ltd.
Key Market Driver
• Improved Diagnostic Techniques.
• For a full, detailed list, view our report.
Key Market Challenge
• High Cost.
• For a full, detailed list, view our report.
Key Market Trend
• Increase in Awareness of HL.
• For a full, detailed list, view our report.
Key Questions Answered in this Report
• What will the market size be in 2018 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

【資料の目次】

01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
03.1 Market Overview
03.2 Product Offerings
03.2.1 Product Profiles
04. Market Research Methodology
04.1 Market Research Process
04.2 Research Methodology
05. Introduction
06. Market Landscape
06.1 Market Overview
06.2 Market Size and Forecast
07. WHO Classification of Hodgkin’s lymphoma
08. Stages of Hodgkin’s Lymphoma
09. Chemotherapy Options for Hodgkin’s Lymphoma
09.1 Five Forces Analysis
10. Market Segmentation by Drug Class
11. Geographical Segmentation
12. Buying Criteria
13. Rate of Incidence and Prevalence
13.1.1 US
13.1.2 UK
14. Pipeline Snapshot
15. Market Growth Drivers
16. Drivers and their Impact
17. Market Challenges
18. Impact of Drivers and Challenges
19. Market Trends
20. Trends and their Impact
21. Vendor Landscape
21.1 Competitive Scenario
21.1.1 Key News
21.1.2 Mergers and Acquisitions
21.2 Market Share Analysis 2013
21.3 Other Prominent Vendors
22. Key Vendor Analysis
22.1 Bristol-Myers Squibb Co.
22.1.1 Key Facts
22.1.2 Business Overview
22.1.3 Product Segmentation
22.1.4 Sales by Geography
22.1.5 Business Strategy
22.1.6 Key Information
22.1.7 SWOT Analysis
22.1.8 Strengths
22.1.9 Weaknesses
22.1.10 Opportunities
22.1.11 Threats
22.2 F. Hoffmann La Roche Ltd.
22.2.1 Key Facts
22.2.2 Business Overview
22.2.3 Business Segmentation
22.2.4 Business Segmentation by Revenue 2012 and 2013
22.2.5 Sales by Geography
22.2.6 Business Strategy
22.2.7 Key Information
22.2.8 SWOT Analysis
22.2.9 Strengths
22.2.10 Weaknesses
22.2.11 Opportunities
22.2.12 Threats
22.3 Merck & Co. Inc.
22.3.1 Key Facts
22.3.2 Business Overview
22.3.3 Business Segmentation by Revenue 2013
22.3.4 Business Segmentation by Revenue 2012 and 2013
22.3.5 Sales by Geography
22.3.6 Business Strategy
22.3.7 Key Developments
22.3.8 SWOT Analysis
22.3.9 Strengths
22.3.10 Weaknesses
22.3.11 Opportunities
22.3.12 Threats
22.4 Pfizer Inc.
22.4.1 Key Facts
22.4.2 Business Overview
22.4.3 Business Segmentation by Revenue 2013
22.4.4 Business Segmentation by Revenue 2012 and 2013
22.4.5 Sales by Geography
22.4.6 Business Strategy
22.4.7 Key Developments
22.4.8 SWOT Analysis
22.4.9 Strengths
22.4.10 Weaknesses
22.4.11 Opportunities
22.4.12 Threats
23. Other Reports in this Series

List of Exhibits
Exhibit 1: Market Research Methodology
Exhibit 2: Global Hodgkin’s Lymphoma Therapeutics Market 2013-2018 (US$ million)
Exhibit 3: NCI Lymphoma Research Portfolio 2013
Exhibit 4: Global Hodgkin’s Lymphoma Therapeutics Market Segmentation by Drug Class
Exhibit 5: Global Hodgkin’s Lymphoma Therapeutics Market by Geographical Segmentation 2013
Exhibit 6: Bristol-Myers Squibb Co.: Product Segmentation (Based on Therapeutic Areas)
Exhibit 7: Bristol-Myers Squibb Co.: Sales by Geography 2013
Exhibit 8: Business Segmentation of F. Hoffmann-La Roche Ltd. 2013
Exhibit 9: F. Hoffmann-La Roche Ltd: Business Segmentation by Revenue 2012 and 2013
Exhibit 10: F. Hoffmann-La Roche Ltd: Sales by Geography 2013 (Pharmaceuticals Division)
Exhibit 11: F. Hoffmann-La Roche Ltd: Sales by Geography 2013 (Diagnostics Division)
Exhibit 12: Merck & Co. Inc.: Business Segmentation by Revenue 2013
Exhibit 13: Merck & Co. Inc.: Business Segmentation by Revenue 2012 and 2013 (US$ billion)
Exhibit 14: Merck & Co. Inc.: Sales by Geography 2013
Exhibit 15: Pfizer Inc.: Business Segmentation by Revenue 2013
Exhibit 16: Pfizer Inc.: Business Segmentation by Revenue 2012 and 2013
Exhibit 17: Pfizer Inc.: Sales by Geography 2013



【掲載企業】

Bristol Myers Squibb Co., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Pfizer Inc. , 4SC AG, Actinium Pharmaceuticals Inc., Aeterna Zentaris Inc., Affimed Therapeutics AG, Hospira Inc., Incyte Corp., Novartis AG, Philogen S.p.A., Seattle Genetics Inc., SigmaTau Pharmaceuticals Inc., Stemline Therapeutics Inc., Teva Pharmaceutical Industries Ltd

【資料のキーワード】

ホジキンリンパ腫、治療、薬、抗腫瘍性アルキル化薬

【調査方法】

一次資料による調査(業界専門家、ベンダー、代理店、顧客等を対象にしたデプスインタビュー調査など)及び二次資料による調査(Technavio独自のプラットフォーム、産業書籍、企業報告書、ニュース記事、アナリストレポート、貿易協会、政府機関発行データなど)

★調査レポート[世界のホジキンリンパ腫治療/医薬品市場(2014-2018)] (Global Hodgkins Lymphoma Therapeutics Market 2014-2018 / IRTNTR3907)販売に関する免責事項
[世界のホジキンリンパ腫治療/医薬品市場(2014-2018)] (Global Hodgkins Lymphoma Therapeutics Market 2014-2018 / IRTNTR3907)についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆